BiotechTube
Kryptos Biotechnologies

Kryptos Biotechnologies

San Diego, United States· Est.
kryptosbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Kryptos Biotechnologies is a private, venture-backed diagnostics company leveraging its proprietary photothermal heating technology to create ultrafast, accurate PCR systems for decentralized clinical settings. Its lead application is an integrated sample-to-answer molecular diagnostic platform for infectious diseases, delivering results in approximately 25 minutes. The company has secured significant non-dilutive funding through grants like the NIH RADx and the RIGHT Foundation, alongside a $10 million Series A round led by Osang Healthcare, and has established a strategic partnership and license agreement with LG Chem. Kryptos operates in the high-growth point-of-care diagnostics market, aiming to translate technological speed and simplicity into improved clinical decision-making.

Infectious Diseases

Technology Platform

Proprietary Photothermal Heating technology using an optical thin film to convert light to heat, enabling ultrafast and precise Photonic PCR for molecular diagnostics and life science applications.

Funding History

2
Total raised:$10M
Series A$8M
Seed$2M

Opportunities

The growing demand for rapid, accurate point-of-care molecular diagnostics presents a large market opportunity, accelerated by the COVID-19 pandemic.
The company's 25-minute PCR system addresses a critical need for faster clinical decision-making in decentralized settings like clinics and ERs.
Its platform technology also allows for potential menu expansion into other disease areas and applications in life science research tools.

Risk Factors

Key risks include the technical and regulatory challenges of bringing a novel diagnostic system to market, including achieving FDA clearance and a CLIA-waiver.
The company faces intense competition from established players and new entrants in the point-of-care molecular space.
Successful commercialization also depends on building a sales channel, securing reimbursement, and driving adoption in a cost-conscious healthcare system.

Competitive Landscape

Kryptos competes in the point-of-care molecular diagnostics market against established companies like Cepheid (GeneXpert) and bioMérieux (BioFire FilmArray), which offer robust systems with broad test menus. It also faces competition from newer entrants developing rapid PCR and isothermal amplification technologies. Kryptos's key differentiator is its photothermal heating technology, which promises faster time-to-result (25 minutes sample-to-answer) and a potentially simpler, more robust system architecture.

More companies in Diagnostics & Precision Medicine →More companies in United States →